2023-05-31
CMS Obtained Exclusive License of a Regenerative Medical Aesthetic Product
CMS Obtained Exclusive License of a Regenerative Medical Aesthetic Product On May 30, the subsidiary of China Medical System Holdings Limited (“CMS” or the “Group”) – a dermatology and medical aesthetic company “CMS Aesthetics” entered into an exclusive license agreement with Jiangsu Xihong Biopharma Co., Ltd.(“Xihong Biopharma”) for Poly-L-lactic Acid Microparticle Filler Injection (the “Product”). In accordance with the license agreement, CMS Aesthetics obtained an exclusive license to promote, market and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region and Taiwan. The exclusive license period shall begin from the date of the approval of the registration certificate of class III medical device of the Product in Mainland China and shall last until the tenth anniversary of the aforementioned date of approval. Upon the expiration of the aforementioned term, the license period may automatically be extended for another period of ten years thereafter if it complies with […]
Learn More